Synaptogenix Inc
NASDAQ:SNPX
Intrinsic Value
Synaptogenix, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one SNPX stock under the Base Case scenario is 26.81 USD. Compared to the current market price of 4.83 USD, Synaptogenix Inc is Undervalued by 82%.
Valuation Backtest
Synaptogenix Inc
Run backtest to discover the historical profit from buying and selling SNPX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Synaptogenix Inc
Current Assets | 30.5m |
Cash & Short-Term Investments | 28.7m |
Other Current Assets | 1.9m |
Non-Current Assets | 580.9k |
Long-Term Investments | 562.4k |
PP&E | 18.5k |
Current Liabilities | 4.3m |
Accounts Payable | 444.6k |
Accrued Liabilities | 3.8m |
Non-Current Liabilities | 1.3m |
Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Synaptogenix Inc
Revenue
|
0
USD
|
Operating Expenses
|
-8.3m
USD
|
Operating Income
|
-8.3m
USD
|
Other Expenses
|
-5.5m
USD
|
Net Income
|
-13.8m
USD
|
Free Cash Flow Analysis
Synaptogenix Inc
SNPX Profitability Score
Profitability Due Diligence
Synaptogenix Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Synaptogenix Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
SNPX Solvency Score
Solvency Due Diligence
Synaptogenix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Synaptogenix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNPX Price Targets Summary
Synaptogenix Inc
According to Wall Street analysts, the average 1-year price target for SNPX is 14 USD .
Ownership
SNPX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SNPX Price
Synaptogenix Inc
Average Annual Return | 10.63% |
Standard Deviation of Annual Returns | 83.84% |
Max Drawdown | -99% |
Market Capitalization | 5.3m USD |
Shares Outstanding | 1 090 000 |
Percentage of Shares Shorted | 2.81% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing therapeutics for patients with neurodegenerative diseases and developmental disorders. The firm is developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD). Its lead product candidate is bryostatin-1. Bryostatin-1 is a Protein Kinase C Epsilon (PKC e), a and e activator that was originally developed as a potential anticancer drug. The firm is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Contact
IPO
Employees
Officers
The intrinsic value of one SNPX stock under the Base Case scenario is 26.81 USD.
Compared to the current market price of 4.83 USD, Synaptogenix Inc is Undervalued by 82%.